Anthera Pharmaceuticals (ANTH) 2.91 $ANTH
Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update
PR Newswire - Mon Jul 28, 4:40PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
PR Newswire - Mon Jul 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc. (Nasdaq:ITMN-Free Report).
Anthera Acquires Sollpura from Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:20PM CDT
Anthera Pharmaceuticals (ANTH) acquired mid-stage development candidate, Sollpura, from Eli Lilly and Company (LLY).
Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 8:04AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise 23% on the day.
Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company
PR Newswire - Mon Jul 14, 3:42PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced that it has acquired Sollpura (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy ("PERT"
from Eli Lilly and Company. Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases. EPI is characterized by low absorption of fat and other nutrients due to a reduction in digestive enzymes produced by the pancreas.
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Anthera Pharmaceuticals Appoints Brian R. Mueller to Board of Directors
PR Newswire - Mon Jun 23, 4:00PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Brian R. Mueller to its Board of Directors and as Chairman of the Audit Committee of the Board of Directors. Mr. Brian R. Mueller currently serves as Group Vice President, Corporate Controller and Chief Accounting Officer of BioMarin Pharmaceutical Inc., a publicly-traded biopharmaceutical company and has been with BioMarin since 2002. Prior to BioMarin, Mr. Mueller spent a combination of seven years in public accounting in Arthur Andersen, LLP and KPMG, LLP. Mr. Mueller holds a B.S. in accounting from Northern Illinois University.
Anthera Pharmaceuticals names Dr Philip Sager to board
M2 - Mon Jun 16, 3:49AM CDT
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) disclosed on Friday the addition of Philip Sager MD FACC FAHA FHRS to its board of directors.
Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors
PR Newswire - Fri Jun 13, 2:30PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Dr. Philip Sager, MD, FACC, FAHA, FHRS, to its Board of Directors.
Lupus Nephritis - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fdzqtl/lupus_nephritis) has announced the addition of the "Lupus Nephritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Bristol-Myers Squibb Company - Baxter International Inc. - Johnson & Johnson - Biogen Idec Inc. - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Noxxon Pharma AG - Anthera Pharmaceuticals Inc. - Kadmon Pharmaceuticals, LLC - Azano Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/fd..._nephritis
Global Wegener's Granulomatosis Pipeline Report 2014 - 9 Companies Involved in Therapeutics Development
M2 - Fri May 30, 8:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f66gqs/wegeners) has announced the addition of the "Wegener's Granulomatosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wegener's Granulomatosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wegener's Granulomatosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Celltrion, Inc. - Nippon Kayaku Co., Ltd. - Panacea Biotec Limited - Anthera Pharmaceuticals Inc. - Biosidus S.A. - Aprogen, Inc. - Curaxys, S.L. - Epirus Biopharmaceuticals, Inc. Scope - The report provides a snapshot of the global therapeutic landscape of Wegener's Granulomatosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Wegener's Granulomatosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wegener's Granulomatosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Wegener's Granulomatosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/f66gqs/wegeners
Anthera Pharmaceuticals Announces Personnel Changes
PR Newswire - Mon Mar 31, 3:30PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Steven Engle to and the departure of Dr. James Healy, MD, PhD from its Board of Directors.
Anthera Pharmaceuticals Reports 2013 Fourth Quarter And Fiscal Year Financial Results and Operational Update
PR Newswire - Wed Mar 12, 5:01PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the fourth quarter and year ended December 31, 2013.
Global Systemic Lupus Erythematosus and Lupus Nephritis Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/3dtg7v/pharmapoint) has announced the addition of the "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022" report to their offering. Sales for SLE and LN by Region, 2012-2022 2012 Systemic Lupus Erythematosus (SLE) drug sales to be over $473.6m across the seven major markets covered in this report: US, France, Germany, Italy, Spain, UK and Japan. By the end of the forecast period in 2022, sales will grow to over $1.1 billion with a CAGR of 9.36%. Focusing on Lupus Nephritis (LN), The authors estimates 2012 drug sales to be over $216.6m across the seven major markets covered in this report. By the end of the forecast period in 2022, sales will grow to over $505.9m with a CAGR of 8.86%. The growth in the SLE and LN therapeutics will be driven by: - Increasing uptake of biologics, including GlaxoSmithKline's Benlysta (belimumab), the only approved biologic for SLE, and off-label use of Roche's Rituxan - The launch of Benlysta in Japan in 2016 - The launch of new biologic drugs during the second half of the forecast period - The increasing number of prevalent cases of SLE and LN The uptake of new biologic drugs that will enter the SLE and LN markets will be initially low. Biologic drugs will primarily target lupus patients with high disease activity (approximately 10%-15% of all SLE patients) and therefore, currently marketed biologic dugs and new entrants will compete for a small segment of the total SLE patient population. This view is based on the available clinical trial data to date for Benlysta, the clinical trial design for current pipeline products and The authors's primary research (conducted in July-August 2013). Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook Companies Mentioned - GlaxoSmithKline - Roche - UCB - Eli Lilly and Company - Bristol-Myers Squibb - Anthera Pharmaceuticals - ImmuPharma - Merck Serono For more information visit http://www.researchandmarkets.com/research/3d...harmapoint
Lupus Nephritis Global Clinical Trials Review, H1, 2014 Research Report
M2 - Mon Feb 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/lt4bvv/lupus_nephritis) has announced the addition of the "Lupus Nephritis Global Clinical Trials Review, H1, 2014" report to their offering. Lupus Nephritis Global Clinical Trials Review, H1, 2014" provides data on the Lupus Nephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lupus Nephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lupus Nephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: List of Tables List of Figures Introduction Lupus Nephritis Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials Latest Clinical Trials News on Lupus Nephritis Clinical Trial Profiles Clinical Trial Overview of Top Companies Clinical Trial Overview of Novartis AG Clinical Trial Overview of Astellas Pharma Inc. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Clinical Trial Overview of Biogen Idec Inc. Clinical Trial Overview of Anthera Pharmaceuticals Inc. Clinical Trial Overview of Teva Pharmaceutical Industries Limited Clinical Trial Overview of La Jolla Pharmaceutical Company Clinical Trial Overview of E. Merck KG Clinical Trial Overview of Bristol-Myers Squibb Company Clinical Trial Overview of Aurinia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government Clinical Trial Overview of Nanjing University Clinical Trial Overview of National Institute of Arthritis and Musculoskeletal and Skin Diseases Clinical Trial Overview of Sun Yat-sen University Clinical Trial Overview of Faculty of Pharmaceutical Sciences, Chulalongkorn University Clinical Trial Overview of Chinese University of Hong Kong Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases Clinical Trial Overview of All India Institute of Medical Sciences Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases Clinical Trial Overview of Zhejiang University Clinical Trial Overview of The Rogosin Institute Five Key Clinical Profiles Appendix For more information visit http://www.researchandmarkets.com/research/lt..._nephritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nephropathy - Pipeline Review, H2 2013 Report Available Now
M2 - Fri Feb 14, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/d4j7jb/nephropathy) has announced the addition of the "Nephropathy - Pipeline Review, H2 2013" report to their offering. 'Nephropathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Nephropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nephropathy. Scope - A snapshot of the global therapeutic scenario for Nephropathy. - A review of the Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Nephropathy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Nephropathy Overview Therapeutics Development Pipeline Products for Nephropathy - Overview Pipeline Products for Nephropathy - Comparative Analysis Nephropathy - Therapeutics under Development by Companies Nephropathy - Therapeutics under Investigation by Universities/Institutes Nephropathy - Pipeline Products Glance Nephropathy - Products under Development by Companies Nephropathy - Products under Investigation by Universities/Institutes Nephropathy - Companies Involved in Therapeutics Development Nephropathy - Therapeutics Assessment Drug Profiles rituximab - Drug Profile blisibimod - Drug Profile BMS-813160 - Drug Profile IgA Proteases For Nephropathy - Drug Profile R&D Progress PRM-151 - Drug Profile TRPC4/C5 Antagonist - Drug Profile IkT-001 Pro - Drug Profile IKT-014 - Drug Profile MS-417 - Drug Profile R&D Progress Featured News & Press Releases Companies Mentioned Bristol-Myers Squibb Company Promedior, Inc. Hydra Biosciences, Inc. Anthera Pharmaceuticals Inc. IGAN Biosciences Inhibikase Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/d4...ephropathy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Thirty-Eight Percent of Workers Have Dated a Co-Worker, Finds CareerBuilder Survey
PR Newswire - Thu Feb 13, 5:00AM CST
Looking for a Valentine? The office may be a good place to start. CareerBuilder's annual survey on office romance found nearly two in five (38 percent) U.S. workers have dated someone who worked for the same company, and 16 percent said they have done so more than once.
Anthera Pharmaceuticals to Present at Leerink Swann, Cowen & Co., and BIO CEO Healthcare Conferences
PR Newswire - Thu Jan 30, 3:42PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update on the progress of the Company's development programs including additional plans for blisibimod beyond autoimmune disorders at three conferences in February and early March.
PSM Holdings, Inc. (PSMH) Announces Additions to its Approved States List
PR Newswire - Thu Jan 30, 8:00AM CST
PSM Holdings, Inc. (OTCBB: PSMH), announces the expansion of PrimeSource Mortgage, Inc. into the states of Arizona and Virginia.
FLG Partners Announces Chris Lowe as a New Partner
Marketwire - Tue Jan 28, 12:09PM CST
FLG Partners, LLC (www.flgpartners.com), announced today the addition of a new partner to the consulting and services firm, bringing the number of partners to 23.
Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update
PR Newswire - Mon Jul 28, 4:40PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
PR Newswire - Mon Jul 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc. (Nasdaq:ITMN-Free Report).
Anthera Acquires Sollpura from Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:20PM CDT
Anthera Pharmaceuticals (ANTH) acquired mid-stage development candidate, Sollpura, from Eli Lilly and Company (LLY).
Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 8:04AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise 23% on the day.
Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company
PR Newswire - Mon Jul 14, 3:42PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced that it has acquired Sollpura (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy ("PERT"
from Eli Lilly and Company. Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases. EPI is characterized by low absorption of fat and other nutrients due to a reduction in digestive enzymes produced by the pancreas. Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Anthera Pharmaceuticals Appoints Brian R. Mueller to Board of Directors
PR Newswire - Mon Jun 23, 4:00PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Brian R. Mueller to its Board of Directors and as Chairman of the Audit Committee of the Board of Directors. Mr. Brian R. Mueller currently serves as Group Vice President, Corporate Controller and Chief Accounting Officer of BioMarin Pharmaceutical Inc., a publicly-traded biopharmaceutical company and has been with BioMarin since 2002. Prior to BioMarin, Mr. Mueller spent a combination of seven years in public accounting in Arthur Andersen, LLP and KPMG, LLP. Mr. Mueller holds a B.S. in accounting from Northern Illinois University.
Anthera Pharmaceuticals names Dr Philip Sager to board
M2 - Mon Jun 16, 3:49AM CDT
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) disclosed on Friday the addition of Philip Sager MD FACC FAHA FHRS to its board of directors.
Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors
PR Newswire - Fri Jun 13, 2:30PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Dr. Philip Sager, MD, FACC, FAHA, FHRS, to its Board of Directors.
Lupus Nephritis - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fdzqtl/lupus_nephritis) has announced the addition of the "Lupus Nephritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Bristol-Myers Squibb Company - Baxter International Inc. - Johnson & Johnson - Biogen Idec Inc. - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Noxxon Pharma AG - Anthera Pharmaceuticals Inc. - Kadmon Pharmaceuticals, LLC - Azano Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/fd..._nephritis
Global Wegener's Granulomatosis Pipeline Report 2014 - 9 Companies Involved in Therapeutics Development
M2 - Fri May 30, 8:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f66gqs/wegeners) has announced the addition of the "Wegener's Granulomatosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wegener's Granulomatosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wegener's Granulomatosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Celltrion, Inc. - Nippon Kayaku Co., Ltd. - Panacea Biotec Limited - Anthera Pharmaceuticals Inc. - Biosidus S.A. - Aprogen, Inc. - Curaxys, S.L. - Epirus Biopharmaceuticals, Inc. Scope - The report provides a snapshot of the global therapeutic landscape of Wegener's Granulomatosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Wegener's Granulomatosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wegener's Granulomatosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Wegener's Granulomatosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/f66gqs/wegeners
Anthera Pharmaceuticals Announces Personnel Changes
PR Newswire - Mon Mar 31, 3:30PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Steven Engle to and the departure of Dr. James Healy, MD, PhD from its Board of Directors.
Anthera Pharmaceuticals Reports 2013 Fourth Quarter And Fiscal Year Financial Results and Operational Update
PR Newswire - Wed Mar 12, 5:01PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the fourth quarter and year ended December 31, 2013.
Global Systemic Lupus Erythematosus and Lupus Nephritis Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/3dtg7v/pharmapoint) has announced the addition of the "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022" report to their offering. Sales for SLE and LN by Region, 2012-2022 2012 Systemic Lupus Erythematosus (SLE) drug sales to be over $473.6m across the seven major markets covered in this report: US, France, Germany, Italy, Spain, UK and Japan. By the end of the forecast period in 2022, sales will grow to over $1.1 billion with a CAGR of 9.36%. Focusing on Lupus Nephritis (LN), The authors estimates 2012 drug sales to be over $216.6m across the seven major markets covered in this report. By the end of the forecast period in 2022, sales will grow to over $505.9m with a CAGR of 8.86%. The growth in the SLE and LN therapeutics will be driven by: - Increasing uptake of biologics, including GlaxoSmithKline's Benlysta (belimumab), the only approved biologic for SLE, and off-label use of Roche's Rituxan - The launch of Benlysta in Japan in 2016 - The launch of new biologic drugs during the second half of the forecast period - The increasing number of prevalent cases of SLE and LN The uptake of new biologic drugs that will enter the SLE and LN markets will be initially low. Biologic drugs will primarily target lupus patients with high disease activity (approximately 10%-15% of all SLE patients) and therefore, currently marketed biologic dugs and new entrants will compete for a small segment of the total SLE patient population. This view is based on the available clinical trial data to date for Benlysta, the clinical trial design for current pipeline products and The authors's primary research (conducted in July-August 2013). Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook Companies Mentioned - GlaxoSmithKline - Roche - UCB - Eli Lilly and Company - Bristol-Myers Squibb - Anthera Pharmaceuticals - ImmuPharma - Merck Serono For more information visit http://www.researchandmarkets.com/research/3d...harmapoint
Lupus Nephritis Global Clinical Trials Review, H1, 2014 Research Report
M2 - Mon Feb 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/lt4bvv/lupus_nephritis) has announced the addition of the "Lupus Nephritis Global Clinical Trials Review, H1, 2014" report to their offering. Lupus Nephritis Global Clinical Trials Review, H1, 2014" provides data on the Lupus Nephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lupus Nephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lupus Nephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: List of Tables List of Figures Introduction Lupus Nephritis Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials Latest Clinical Trials News on Lupus Nephritis Clinical Trial Profiles Clinical Trial Overview of Top Companies Clinical Trial Overview of Novartis AG Clinical Trial Overview of Astellas Pharma Inc. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Clinical Trial Overview of Biogen Idec Inc. Clinical Trial Overview of Anthera Pharmaceuticals Inc. Clinical Trial Overview of Teva Pharmaceutical Industries Limited Clinical Trial Overview of La Jolla Pharmaceutical Company Clinical Trial Overview of E. Merck KG Clinical Trial Overview of Bristol-Myers Squibb Company Clinical Trial Overview of Aurinia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government Clinical Trial Overview of Nanjing University Clinical Trial Overview of National Institute of Arthritis and Musculoskeletal and Skin Diseases Clinical Trial Overview of Sun Yat-sen University Clinical Trial Overview of Faculty of Pharmaceutical Sciences, Chulalongkorn University Clinical Trial Overview of Chinese University of Hong Kong Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases Clinical Trial Overview of All India Institute of Medical Sciences Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases Clinical Trial Overview of Zhejiang University Clinical Trial Overview of The Rogosin Institute Five Key Clinical Profiles Appendix For more information visit http://www.researchandmarkets.com/research/lt..._nephritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nephropathy - Pipeline Review, H2 2013 Report Available Now
M2 - Fri Feb 14, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/d4j7jb/nephropathy) has announced the addition of the "Nephropathy - Pipeline Review, H2 2013" report to their offering. 'Nephropathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Nephropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nephropathy. Scope - A snapshot of the global therapeutic scenario for Nephropathy. - A review of the Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Nephropathy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Nephropathy Overview Therapeutics Development Pipeline Products for Nephropathy - Overview Pipeline Products for Nephropathy - Comparative Analysis Nephropathy - Therapeutics under Development by Companies Nephropathy - Therapeutics under Investigation by Universities/Institutes Nephropathy - Pipeline Products Glance Nephropathy - Products under Development by Companies Nephropathy - Products under Investigation by Universities/Institutes Nephropathy - Companies Involved in Therapeutics Development Nephropathy - Therapeutics Assessment Drug Profiles rituximab - Drug Profile blisibimod - Drug Profile BMS-813160 - Drug Profile IgA Proteases For Nephropathy - Drug Profile R&D Progress PRM-151 - Drug Profile TRPC4/C5 Antagonist - Drug Profile IkT-001 Pro - Drug Profile IKT-014 - Drug Profile MS-417 - Drug Profile R&D Progress Featured News & Press Releases Companies Mentioned Bristol-Myers Squibb Company Promedior, Inc. Hydra Biosciences, Inc. Anthera Pharmaceuticals Inc. IGAN Biosciences Inhibikase Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/d4...ephropathy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Thirty-Eight Percent of Workers Have Dated a Co-Worker, Finds CareerBuilder Survey
PR Newswire - Thu Feb 13, 5:00AM CST
Looking for a Valentine? The office may be a good place to start. CareerBuilder's annual survey on office romance found nearly two in five (38 percent) U.S. workers have dated someone who worked for the same company, and 16 percent said they have done so more than once.
Anthera Pharmaceuticals to Present at Leerink Swann, Cowen & Co., and BIO CEO Healthcare Conferences
PR Newswire - Thu Jan 30, 3:42PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update on the progress of the Company's development programs including additional plans for blisibimod beyond autoimmune disorders at three conferences in February and early March.
PSM Holdings, Inc. (PSMH) Announces Additions to its Approved States List
PR Newswire - Thu Jan 30, 8:00AM CST
PSM Holdings, Inc. (OTCBB: PSMH), announces the expansion of PrimeSource Mortgage, Inc. into the states of Arizona and Virginia.
FLG Partners Announces Chris Lowe as a New Partner
Marketwire - Tue Jan 28, 12:09PM CST
FLG Partners, LLC (www.flgpartners.com), announced today the addition of a new partner to the consulting and services firm, bringing the number of partners to 23.
